We are giving life to new classes of medicine to change the lives of patients with devastating diseases

We are giving life to new classes of medicine to change the lives of patients with devastating diseases

Strong track record of clinical success, outperforming the biopharma industry average by 6x1
0
New therapeutics and therapeutic candidates generated from PureTech's R&D engine
0
Clinical indications being pursued by PureTech or its Founded Entities
0
Has been filed for FDA approval
0
Taken from inception at PureTech to FDA and EU regulatory clearances
Unlocking the Potential of Validated Efficacy
We do this by enhancing on-target efficacy, enabling oral administration or improving tolerability to unlock new classes of medicine
Seasoned Senior Leadership
Our team oversaw R&D of therapeutics supporting 27 regulatory approvals and served in the C-suite of companies acquired for more than $14B in aggregate
Our network of scientific collaborators enables us to identify or co-invent key intellectual property before it's published in major journals
Our network of scientific collaborators enables us to identify or co-invent key intellectual property before it's published in major journals

News & Press

Press releases
2023-09-28
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
Press releases
2023-09-27
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer

Clinical success is measured as the probability of transition success from Phase 1 to Phase 3. The cumulative percentages are calculated by multiplying the individual phase percentages. Industry average data measures the probability of clinical trial success of therapeutics by calculating the number of programs progressing to the next phase vs. the number progressing and suspended (Phase 1=52%, Phase 2=29%, Phase 3=58%). BIO, PharmaIntelligence, QLS (2021) Clinical Development Success Rates 2011 – 2020. This report did not include therapeutics regulated as devices. PureTech aggregate percentages including all therapeutic candidates advanced through at least Phase 1 by PureTech or its Founded Entities from 2009 onward, using the aforementioned calculation method based on the following individual phase percentages, Phase 1 (75%), Phase 2 (83%), Phase 3 (75%), last reviewed on June 30, 2023; Phase 2 and Phase 3 percentages include some therapeutic candidates where a previous trial was not conducted by PureTech or its Founded Entities because it was not required by regulatory authority.